SITE006-0211

SITE006 (GBR) › SITE006-0211

SITE006-0211

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-05-06

enrolled

AEs

3

Serious

3

Dropout signal

–

Adverse events

3

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-15 (study day 66); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-20 (study day 40); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-10 (study day 30); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.